History

While researching cell transplantation in 1993-1994, Eskil Elmér and his colleagues made an unexpected discovery. The experiment itself failed, but the researchers discovered that cyclosporine-A protected nerve cells powerfully when it crossed the blood-brain barrier. This discovery marked the start of basic research in the field. The scientific work publishing the first findings had been cited 141 times by June 2008.

NeuroVive was set up in 2000 as a subsidiary of Maas Biolab, LLC (founded in 1997) with the aim of commercializing work on developing cyclosporine-based drugs for acute conditions and illnesses affecting the brain.

The basic research has been underway continuously since 1993, and a number of independent international teams of researchers have confirmed, through tests on animals, that cyclosporine-A provides powerful protection for nerve cells in cases of traumatic brain damage, stroke and brain damage during cardiac arrest.

The last batch of NeuroSTAT® was manufactured in 2005. The product is now fully developed and is stable for at least three years. The next step is clinical trials in humans in the field of traumatic brain injury.